Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder

NCT ID: NCT01798914


Title
Patient Transfer Program for Transitioning From Exubera® (Insulin Human [rDNA Origin]) Inhalation Powder to Technosphere® Insulin (Insulin Human [rDNA Origin]) Inhalation Powder
Purpose
The purpose of this study is to allow patients with specific needs for inhaled insulin to continue with inhaled insulin therapy using Technosphere Insulin after Exubera was withdrawn from the market.
Details
A Phase 3, open label, multicenter, safety follow up trial to convert the treatment of subjects currently using Exubera to treatment with TI Inhalation Powder
Conditions
Type 1 Diabetes, Type 2 Diabetes
Keywords
Source
Mannkind Corporation
Sponsors
Mannkind Corporation
Status
No longer available
Acronym
Last Updated
18 Jan 2016
URL
Official Link
Locations
United States